Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that company
John Wiley & Sons, Inc. Common Stock (NYSE:JW) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.37 by 45.95 percent. This is a 28.57 percent increase over earnings of $0.42
The U.S. Food and Drug Administration (FDA) cleared Nuvectis Pharma’s (NASDAQ: NVCT) Investigational New Drug Application (IND) for NXP800, which includes the Phase 1 clinical trial protocol.